Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cost-utility analysis of antiviral use under pandemic influenza using a novel approach - linking pharmacology, epidemiology and heath economics.
Wu DBC, Chaiyakunapruk N, Pratoomsoot C, Lee KKC, Chong HY, Nelson RE, Smith PF, Kirkpatrick CM, Kamal MA, Nieforth K, Dall G, Toovey S, Kong DCM, Kamauu A, Rayner CR. Wu DBC, et al. Among authors: nieforth k. Epidemiol Infect. 2018 Mar;146(4):496-507. doi: 10.1017/S0950268818000158. Epub 2018 Feb 15. Epidemiol Infect. 2018. PMID: 29446343 Free PMC article.
Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics.
Kamal MA, Smith PF, Chaiyakunapruk N, Wu DBC, Pratoomsoot C, Lee KKC, Chong HY, Nelson RE, Nieforth K, Dall G, Toovey S, Kong DCM, Kamauu A, Kirkpatrick CM, Rayner CR. Kamal MA, et al. Among authors: nieforth k. Br J Clin Pharmacol. 2017 Jul;83(7):1580-1594. doi: 10.1111/bcp.13229. Epub 2017 Feb 20. Br J Clin Pharmacol. 2017. PMID: 28176362 Free PMC article.
Cost-Utility Analysis of Optimal Dosing of Oseltamivir Under Pandemic Influenza Using a Novel Approach: Linking Health Economics and Transmission Dynamic Models.
Wu DB, Chaiyakunapruk N, Pratoomsoot C, Lee KK, Chong HY, Nelson RE, Smith PF, Kirkpatrick C, Kamal MA, Nieforth K, Dall G, Toovey S, Kong DC, Kamauu A, Rayner C. Wu DB, et al. Among authors: nieforth k. Value Health. 2014 Nov;17(7):A807. doi: 10.1016/j.jval.2014.08.527. Epub 2014 Oct 26. Value Health. 2014. PMID: 27203045 Free article. No abstract available.
Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans.
Patel K, Kirkpatrick CM, Nieforth KA, Chanda S, Zhang Q, McClure M, Fry J, Symons JA, Blatt LM, Beigelman L, DeVincenzo JP, Huntjens DR, Smith PF. Patel K, et al. Among authors: nieforth ka. J Antimicrob Chemother. 2019 Feb 1;74(2):442-452. doi: 10.1093/jac/dky415. J Antimicrob Chemother. 2019. PMID: 30376079 Clinical Trial.
Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment.
Brennan BJ, Wang K, Blotner S, Magnusson MO, Wilkins JJ, Martin P, Solsky J, Nieforth K, Wat C, Grippo JF. Brennan BJ, et al. Among authors: nieforth k. Antimicrob Agents Chemother. 2013 Dec;57(12):6097-105. doi: 10.1128/AAC.00608-13. Epub 2013 Sep 30. Antimicrob Agents Chemother. 2013. PMID: 24080649 Free PMC article. Clinical Trial.
45 results